Oral tablet Sunitinib lowers risk of kidney cancer return: Study

Ryan Maass
GUILDFORD, England, Oct. 11 (UPI) — Doctors say a successful clinical trial of the oral tablet Sunitinib in kidney cancer patients shows it reduces the likelihood of cancer returning. …read more

Source:: National and World Stories

      

You must be logged in to post a comment Login